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ense.Abstract Background: It was observed during dissection of heavy deposits of axillary lymph
nodes (LNs) in breast cancer that there were grossly positive LNs outside the conﬁnes of classical
axillary dissection.
Aim of study: To know the extent of LN metastases in these new basins by dissecting and labeling
them separately, for pathological examination and proper staging of those patients.
Patients and methods: From 2005 to 2009, 59 private patients with breast cancer who had positive
axillary LNs were subjected to axillary dissection with accurate leveling according to its relation to
pectoralis minor. In addition to the classical three levels, the brachial, thoracoacromial, humeral,
scapular and Rotter’s lymph nodes were dissected.
Results: Levels I, II and III axillary LNs were involved in 91.5%, 62.7%, and 52.5%, respectively.
Skip metastases (without the involvement of level one) were found in 5/59 patients (8.4%). Brachial,
acromiothoracic, humeral and Rotter’s LNs were involved in 10.1%, 15.2%, 5% and 1.7%, respec-
tively, with no metastatic deposits encountered in scapular LNs. In our patients, lymphedema of the
ipsilateral upper limb was nearly of the same incidence as after classical axillary dissection.m (I. Fakhr).
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26 M. Khafagy et al.Conclusion: In addition to the classic complete axillary lymph node dissection (ALND) indicated in
patients with breast cancer with axillary LNs metastases, dissection of the brachial, acromiothoracic,
humeral, Rotter’s and scapular LNs, is recommended for proper staging.
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Figure 2 Lt thoracoacromial LN.Introduction
Carcinoma of the breast is the most common malignant
tumor and is the most common cause of death from
carcinoma in females [1,2]. In the West, widespread use of
mammography has resulted in a marked increase in early
detection of this carcinoma, when it is still microscopic or
localized and small in size. This, however, unfortunately is
not the case for developing countries where breast cancer
mortality is still rising [3].
In the late 19th century, breast cancer was considered a fatal
disease. This began to change in the 1880s when Halsted
described radical mastectomy as the way to treat patients with
breast cancer [4]. This aggressive surgical treatment in which
the breast, axillary LNs, and chest muscles are all removed,
remained the standard of care throughout much of the 20th
century; as late as the early 1970s, so that nearly half (48%) of
breast cancer patients were treated with radical mastectomy.
During the 1970s, however, the Halsted radical mastectomy
was largely abandoned for a less-disﬁguring muscle-sparing
technique called the modiﬁed radical mastectomy; so that by
1981, only 3% of the patients underwent the Halsted mastec-
tomy [5]. The 1980s heralded evenmoreminimally invasive tech-
niques with the advent of breast conservation therapy, in which
an incision is made over the tumor and the tumor is completely
removed with negative margins, leaving behind the normal
breast tissue.During the 1990s, surgical invasivenesswas further
minimized with the emergence of sentinel LN excision [5].
The positivity of axillary LNs for metastases is one of the
most important prognostic parameters in carcinoma of the
breast with sharp differences in survival rates between those
with negative and positive nodes. In addition, the absolute
number of nodes involved, the presence or absence of extran-
odal spread, capsular invasion, and the amount of carcinoma
in the positive nodes (measured by the microscopic size of
the largest nodal metastases) are also prognostically important
with survival rates falling with increased number of nodes
involved (less than 4 versus 4 or more), presence of extranodal
spread and increased amount of tumor in positive nodes [6,7].
Carter and co-workers, in a study on 24,700 patients reported
that the extent of axillary LN involvement in breast cancer is
the dominant prognostic indicator for the development of a
later systemic disease [8].
Complete and detailed axillary dissection in patients with
positive axillary LNs will provide proper staging, accurate
prognosis and optimum loco-regional control [8]. It was
observed during dissection of heavy deposits of axillary LNs
in breast cancer that there were grossly positive LNs outside
the conﬁnes of the classical axillary lymph node dissection
(ALND). Those nodes were found anterior to the brachial
plexus (brachial LNs), around thoracoacromial vessels (thora-
coacromial LNs), humeral LNs, just lateral to the origin of
thoracodorsal artery, scapular LNs (inter-nerve LNs betweennerve to lattismus dorsi and long thoracic nerve) in addition
to Rotter’s LNs. The aim of the present study is to determine
the extent of LN metastases in these new basins by dissecting
and labeling them separately, for pathological examination
and hence a proper staging of those patients.Patients and methods
The study population consisted of patients with operable
breast cancer who underwent surgery for invasive breast can-
cer between January 2005 and December 2009. According to
the international TNM staging system by the American Joint
Figure 3 Lt humeral LN.
Table 1 Distribution of LN metastases in different levels and
groups of axillary LNs in 59 breast cancer patients under study.
Nodal status (n= 59) Number of patients Percentage (%)
Patients with positive classical axillary groups
Metastases in level I
axillary LN
54 91.5
Metastases in level II
axillary LN
37 62.7
Metastases in level III
axillary LN
31 50.8
Isolated positive level I
axillary LN
18 30.5
Positive level I and II
with negative level III
11 18.6
Skip metastases 5 8.4
Patients with positive new
axillary groups
14 23.7
Positive Rotter’s LN 1 1.7
Positive brachial LN 6 10.1
Positive acromiothoracic
LN
9 15.2
Positive humeral LN 3 5.08
Positive scapular LN 0 0.0
Figure 4 Relation between the number of positive LN in the
three levels of axillary LNs to that of the positive LNs in the newly
dissected LN groups.
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tients with operable T1, T2, T3, with positive LN on ﬁnal
pathological examination, breast cancer were included in the
study. Patients with locally advanced stage III breast cancer
who received pre-operative (neo-adjuvant) chemotherapy were
included in the study whenever down staged.
This prospective study was conducted on 59 private female
patients for whom surgical treatment of the primary tumor
was done according to the standard criteria. Thirty four out
of 59 patients (57.6%) underwent conservative breast surgery,
12 patients underwent modiﬁed radical mastectomy (20.3%)
and 13 patients underwent radical mastectomy (22%).
Complete axillary clearance (levels I, II and III) was done
and each of the three levels was separately marked and submit-
ted for pathological examination. Five separately studied LN
groups were also dissected, namely:
(1) Brachial LNs (Infraclavicular) this is the pad of fat con-
taining LNs anterior and above the cords of brachial
plexus, under the insertion of pectoralis minor muscle
and medial to the coracobrachialis muscle); this pad of
fat which was taken separately was carefully examined
to detect the presence of metastases (Fig. 1).
(2) Thoraco-acromial LNs (surrounding thoraco-acromial
vessels) (Fig. 2).
(3) Humeral LNs (lateral to thoracodorsal vessels) (Fig. 3).
(4) Inter-Pectoral LNs (Rotter’s).
(5) Inter-nerve LNs (scapular).
Pathological analysis of each LN with staining with Hema-
toxin and Eosin was done. Correlation of each of the ﬁve
separately dissected groups of nodes was done with each level
of standard axillary LNs. Results of this study may show the
indication, beneﬁts and sequelae of the dissection of these
additional groups of nodes. Routine postoperative care was
adopted and all patients had an uneventful course. Follow-
up period ranged between 1 and 65 months with special atten-
tion to seroma and arm lymphedema. Lymphedema is deﬁned
as volume difference between the treated and untreated arm of
more than 200 ml, or more than 2 cm difference in the circum-
ference of both arms.Results
The patients’ age ranged between 24 and 77 years (mean
52.9 ± 13 years). Thirty four patients (57.6%) had breast con-
serving surgery (BCS), 12 patients (20.3%) had undergone
modiﬁed radical mastectomy (MRM) and 13 patients (22%)
had radical mastectomy.
Pathological analysis revealed that of the 59 patients, 48 pa-
tients had inﬁltrating duct carcinoma (IDC), eight patients had
invasive lobular carcinoma, two patients had tubular carci-
noma and a single patient had mucinous carcinoma. Among
the 59 patients, two patients (3.4%) were of grade 1, 47
patients (79.9%) were grade of 2, and 10 patients (16.9%) were
of grade 3.
According to the tumor size; 11 patients (18.6%) had T1
tumor, 40 (67.8%) had T2 tumor and 6 (10.2%) had T3 tumor.
Two patients had T4 tumor (3.4%). All patients had N1
Figure 5 Relation between positivity of Level III LN and
positivity in any of the new LN groups.
28 M. Khafagy et al.disease and the metastatic work-up (chest X-ray, Abdominal
and pelvic ultrasound, Bone scan) was free of metastases.
When the axillary dissection materials were reviewed, the
mean number of dissected LNs from the 59 patients was
24.1 ± 8.7, and the mean number of metastatic LNs was
9.9 ± 9.1. Among the 59 patients with positive LNs: Twenty
patients were pN1a (metastasis in 1–3 axillary LNs), 19
patients (32.2%) were pN2a (metastasis in 4–9 axillary LNs;
and 19 patients (33.9%) were pN3 (metastasis in 10 or more
axillary LNs) (32.2%). Extra nodal spread was present in 20
patients (33.9%).
Level I axillary LNs were involved in 54 of the 59 patients
(91.5%); level two LNs were involved in 37 of the 59 patients
(62.7%), while level three LNs were involved in 31 of the 59
patients (52.5%) (Table 1). Fourteen patients (23.7%) had
metastatic deposits in either Rotter’s, brachial, acromiotho-
racic, or humeral LNs (Table 1).
When level III harbored metastases, 10/31 of patients
(32.3%) had metastatic disease in either brachial, acromiotho-
racic or humeral LNs. When level II harbors metastases (with
negative level III), only 1/11 patients (9%) had metastases in
brachial LNs. While LN metastases were restricted to level I
(with negative level II and level III) 3/18 patients (16.6%)
had metastases in either the brachial, acromiothoracic or hum-
eral LNs. There was a statistically signiﬁcant relation between
LN metastases in the newly dissected groups and more than 10
LN metastases (Fig. 4). Also, a border line signiﬁcance was
found between metastases in new groups and involvement of
level III (Fig. 5).
Eight (13.5%) of our patients had lymphedema of the
ipsilateral upper limb. Two (3.4%) more patients presented
with local recurrence after breast conserving surgery for which
salvage mastectomy was performed.
Discussion
Green and co-workers (2002), revised the sixth edition of the
American Joint Committee on Cancer staging manual in
2002 and introduced new prognostic factors and a new stage
III C in which a new pN3 was introduced. In the revised stag-
ing system, the level of axillary involvement and the number of
metastatic LNs have been accepted as prognostic factors. In
this staging system pN1 = 1–3 positive nodes, pN2 = 4–9
positive nodes and pN3P 10 positive axillary nodes and anypositive LN at the apex of the axilla or infraclavicular node
is pN3 [10,11].
Axillary dissection still offers the most efﬁcient local con-
trol in node-positive patients. It is of no doubt that surgical
therapy still contributes to cure early-breast-cancer patients
and seems to be curative for certain patients with stage-I
carcinoma [12].
It is reasonable to perform a complete axillary node dissec-
tion including level III as we have found that 31 of the 59
patients (52.5%) had metastatic deposits in that level. This
goes with the study done by Ouyang and associates who found
metastases at level III LNs in 18 patients (20.7%) among 87
patients [13].
In another study by Veronesi and associates done on 539
patients with breast cancer, they reported involvement of level
3 in 16.9% of T-l breast cancer patients. Veronesi and associ-
ates stated that the likelihood of involvement of either level II
or III is related to the number of LNs containing metastases in
level I, so when only one node in level I contained metastases
only 8% of patients had involvement of the upper levels of the
axilla. Whereas when level I was involved with two nodes,
25.3% of patients had higher level metastases, and this ratio
rises to 65.8% if level I had four or more LN metastases
[14,15].
In our study, skip metastases (i.e. without level I involve-
ment) was found in ﬁve of the 59 patients (8.4%). All the ﬁve
negative level I patients exhibited skip metastases, two patients
skip to level II only, one patient at level III and two patients at
levels II and III and this was much higher than the study done
by Veronesi et al. on 539 patients and Rosenet and associates
on 1228 patients with breast cancer who reported 0.4% and
0.2% incidence of skip metastases, respectively. The discrep-
ancy between the two previous studies and the present study
can be explained by the fact that both studies were applied
only to early breast cancer [14,16]. A higher number of skip
metastases was found in the study conducted by Zhong and
Zhi (2008) who found skip metastases in 119/814 patients
(14.6%) with positive axillae [17].
The risk of axillary failure appears to be inversely related to
the number of LNs removed as reported by Graverson and his
colleagues in their study done on risk of axillary recurrence
following limited axillary dissection, where the risk of axillary
failure was 5–21% when <5 LNs were removed whereas it
decreased to 5% if more than ﬁve LNs were dissected [15].
Kiricuta and Tausch constructed a mathematical method to
predict the number of nodes that must be removed, based on
the data from 1446 axillary dissections performed at the Milan
NCI on T-l tumors; they stated that at least 10 negative LNs
predicted that the remainder of the axilla did not contain
metastases with 90% certainty [18].
Among women undergoing mastectomy for breast cancer,
10–15% will have a recurrence of cancer in the chest wall or
axillary LNs within 10 years [19]. Similarly, among women
undergoing breast conservation therapy plus radiation ther-
apy, 10–15% will have in-breast cancer recurrence or recur-
rence in axillary LNs within 10 years [19]. Axillary failure
rates are low, however there is a 21% risk of developing
axillary recurrence in patients not undergoing treatment of
the axilla. For this reason, the levels I and II axillary LN dis-
section has been considered the standard of care in early-stage,
node-negative cancer [20,21]. In the present study which was
done on 59 patients, after a follow up period of 1–65 months
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failures.
Kuru et al. reported that apical (Infraclavicular) metastasis
was an independent predictor of survival in node-positive
patients with breast carcinoma and was associated with poor
survival rates in a series of 1277 patients [22]. Infraclavicular
LN metastasis causes migration to stage IIIC, even in early
stage patients with T1 tumors, and shifts these patients to a
locally advanced stage. In the study done by Gu¨ven et al.
(2007), among 44 patients who were treated with mastectomy,
11 patients (25%) were reclassiﬁed as stage IIIC because of the
infraclavicular LN metastasis. Seven of these patients (63.6%)
were in stage I or II, according to the previous staging system
but became locally advanced according to the latest system
[23]. In the present study brachial LNs were involved in six
patients (10.1%).
Although there is some controversy regarding the percent-
age of patients that may develop metastases to interpectoral
nodes, as many as 14% of the patients of operable breast
cancer have positive interpectoral nodes at the time of oper-
ation [13,24,25]. In the present study only one patient had
involvement of the interpectoral LN (1.7%). In the study
conducted by Komenaka et al. (2004), four patients (0.1%)
had recurrence at the interpectoral nodes among 4097
patients who underwent surgical management for breast can-
cer. They also concluded that recurrence at the interpectoral
nodes can be the initial site of surgical failure. These nodes
may represent the site of primary drainage in a percentage
of patients [26].
We found in this study that capsular inﬁltration is present
in 20 of the 59 patients (33.9%). In the literature, extracapsular
spread (ECS) is documented in the range of 24–60% of breast
cancer patients. However, it is not clear that ECS was signiﬁ-
cantly associated with supraclavicular, local or axillary recur-
rence [27].
The yield of axillary LN metastases in groups outside the
three levels may increase with step sectioning of axillary LNs
and/or the use of cytokeratin to examine the negative LNs
pathologically. Querzoli and colleagues demonstrated minimal
LN deposits in 13% of pN0 patients. Occult metastases can in-
deed be identiﬁed in up to 30% of patients previously classiﬁed
as pN0 [28]. Studies based on these procedures have shown
that axillary LN microinvasion is a prognostic factor for breast
cancer patients, and is associated with poorer disease-free and
overall survival. As a consequence, micrometastasis (0.21–
2 mm in diameter) has been identiﬁed as a relevant risk factor
and its detection has been introduced in TNM staging proce-
dures (2003 TNM edition). Following these guidelines, isolated
tumor cells or cell deposits smaller than 0.2 mm are currently
required to be classiﬁed as pN0 [11].
It is of great importance to notice that breast cancer pa-
tients in Egypt show a much higher lymph node positivity sta-
tus than their western homologues. Nouh et al. (2004),
published a study on 3755 Egyptian breast cancer patients,
in one, if not the largest, published breast cancer pathological
studies from Egypt. He found that LN metastasis was evident
in 2646 (70.6%) of the total cases, while 1101 cases (29.4%)
were free of metastasis [29]. This is in comparison to the node
positive patients, who constitute 25–40% of the cases in the
west [30,31]. This explains the need to extend the territory of
the axillary lymph node dissection to the adjacent LN groups
described in this study.The most controversial aspect of axillary dissection is its
impact on survival [27]. There are two potential mechanisms
by which residual tumor in the axilla could act as a source
of distant metastases, thereby affecting survival. First, uncon-
trolled loco-regional tumor is a potential source of metastases
and this hypothesis is supported by the work of Arrigada and
colleagues who studied 960 node positive breast cancer pa-
tients treated with modiﬁed radical mastectomy and irradia-
tion, second, uncontrolled axillary disease can act as a
source of tumor reseeding [32]. Other studies were done by
Overgaard and colleagues on 210 breast cancer patients treated
with modiﬁed radical mastectomy versus 241 patients treated
with simple mastectomy and axillary biopsy. They reported a
10 year survival of 58.8% in the axillary dissection group ver-
sus 42.3% for those who had axillary LN biopsy. Conversely,
inadequate treatment of the axilla has been associated with
decreased survival [33].
In the present study, no major complications of axillary
dissection occurred, and complications such as thrombosis
or injury of the axillary vein/artery, damage to the motor
nerves of the axilla were not reported. Regarding the morbid-
ity of the proposed technique of dissecting additional nodal
basins compared retrospectively to similar stages of breast
cancer patients who underwent standard axillary dissection,
the rates of both were similar. The incidence of lymphedema
in this study was (10.1%) which goes with that reported in
the literature (between 6% and 30%) depending upon the
methods to deﬁne it and the adequacy of follow-up. Lymph-
edema remains a signiﬁcant problem even in patients treated
with a level I and II ALND as reported by Lin and col-
leagues [34].
It was recognized that the rates of lymphedema are very
low if the adventitia of the axillary vein is not violated. So
if the surgeon dissects the brachial pad of fat above the axil-
lary vein in order to dissect the brachial LN basin, care
should be taken to not violate the adventitia surrounding
the vein [35].
Conclusion
Complete ALND is recommended in the presence of axillary
LNs metastases, including the three classical levels, brachial,
acromiothoracic, humeral, Rotter’s and scapular LNs in
patients with breast cancer, for proper staging and optimum
regional control. It may result in a better long term survival.
In these new groups, metastatic deposits were found in 14
patients (23.7%) out of the 59 patients with N1 disease. Under-
estimation of the number of positive nodes examined will
result in errors in the assessment of individual risk for loco-
regional control, survival and will adversely impact further
treatment.
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